Abstract
To the Editor: Douglas and colleagues (Jan. 23 issue)(1) report exciting results from their phase 3 trial of teprotumumab therapy for Graves' orbitopa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
